Pre-made Ranibizumab biosimilar ( Fab, anti-VEGFA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-470
Anti-VEGFA therapeutic antibody (Pre-made Ranibizumab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-VEGFA therapeutic antibody (Pre-made Ranibizumab biosimilar,Fab)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||1cz8:HL:YX|
|99% SI Structure||None|
|95-98% SI Structure||1bj1:HL:KJ/6bft:HL:AB|
|Companies||Genentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn|
|Conditions Approved||Choroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy|
|Conditions Active||Retinopathy of prematurity;Polypoidal choroidal vasculopathy|
|Conditions Discontinued||Retinal telangiectasis|